NCT01812551View on ClinicalTrials.gov

Treatment of Low Bone Density in Cystic Fibrosis.

PHASE3CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2007

Conditions
OsteoporosisCystic Fibrosis
Interventions
DRUG

Alendronate

As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).

DRUG

Placebo

Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).

Trial Locations (11)

20145

Istituto Auxologico Italiano IRCCS, Milan

Unknown

CRR Fibrosi Cistica, Divisione Gastroenterologia, Ospedale Bambin Gesù, Vatican City

CRR Fibrosi Cistica, Unità Operativa di Pediatria, Ospedale Misericordia, Grosseto

CRR Fibrosi Cistica, Clinica Pediatrica, Policlinico Universitario di Messina, Messina

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan

CRR Fibrosi Cistica, Dipartimento Pediatria, Università Federico II, Napoli

CRR Fibrosi Cistica Adulti, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano

CRR Fibrosi Cistica, Ospedale dei Bambini, ARNAS Civico, Palermo

CRR Fibrosi Cistica, Dipartimento di Pediatria, Policlinico Umberto I, Roma

CRR Fibrosi Cistica, Divisione di Pediatria, Istituto Burlo Garofolo, Trieste

CRR Fibrosi Cistica, Azienda Ospedalierouniversitaria di Verona, Verona

All Listed Sponsors
collaborator

Fondazione Telethon

OTHER

lead

Istituto Auxologico Italiano

OTHER

NCT01812551 - Treatment of Low Bone Density in Cystic Fibrosis. | Biotech Hunter | Biotech Hunter